BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37555723)

  • 21. T2-FLAIR mismatch sign and machine learning-based multiparametric MRI radiomics in predicting IDH mutant 1p/19q non-co-deleted diffuse lower-grade gliomas.
    Tang WT; Su CQ; Lin J; Xia ZW; Lu SS; Hong XN
    Clin Radiol; 2024 May; 79(5):e750-e758. PubMed ID: 38360515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
    Yokoda RT; Cobb WS; Yong RL; Crary JF; Viapiano MS; Walker JM; Umphlett M; Tsankova NM; Richardson TE
    J Neuropathol Exp Neurol; 2023 Sep; 82(10):845-852. PubMed ID: 37550258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
    Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
    Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deep Learning Radiomics Model of Dynamic Contrast-Enhanced MRI for Evaluating Vessels Encapsulating Tumor Clusters and Prognosis in Hepatocellular Carcinoma.
    Dong X; Yang J; Zhang B; Li Y; Wang G; Chen J; Wei Y; Zhang H; Chen Q; Jin S; Wang L; He H; Gan M; Ji W
    J Magn Reson Imaging; 2024 Jan; 59(1):108-119. PubMed ID: 37078470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
    Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
    Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.
    Galbraith K; Garcia M; Wei S; Chen A; Schroff C; Serrano J; Pacione D; Placantonakis DG; William CM; Faustin A; Zagzag D; Barbaro M; Eibl MDPGP; Shirahata M; Reuss D; Tran QT; Alom Z; von Deimling A; Orr BA; Sulman EP; Golfinos JG; Orringer DA; Jain R; Lieberman E; Feng Y; Snuderl M
    Neuro Oncol; 2024 Jun; 26(6):1042-1051. PubMed ID: 38243818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IDH-mutant astrocytoma with an evolutional progression to CDKN2A/B homozygous deletion and NTRK fusion during recurrence: A case report.
    Kirishima M; Akahane T; Higa N; Suzuki S; Ueno S; Yonezawa H; Uchida H; Hanaya R; Yoshimoto K; Shimajiri S; Kitazono I; Tanimoto A
    Pathol Res Pract; 2022 Nov; 239():154163. PubMed ID: 36265224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Lymphovascular Invasion in Breast Cancer Using a Combined MRI Morphological Features, Radiomics, and Deep Learning Approach Based on Dynamic Contrast-Enhanced MRI.
    Yang X; Fan X; Lin S; Zhou Y; Liu H; Wang X; Zuo Z; Zeng Y
    J Magn Reson Imaging; 2024 Jun; 59(6):2238-2249. PubMed ID: 37855421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI.
    Zhang X; Tian Q; Wang L; Liu Y; Li B; Liang Z; Gao P; Zheng K; Zhao B; Lu H
    J Magn Reson Imaging; 2018 Oct; 48(4):916-926. PubMed ID: 29394005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.
    Ranade M; Epari S; Shetty O; Dhanavade S; Chavan S; Sahay A; Sahu A; Shetty P; Moiyadi A; Singh V; Dasgupta A; Chatterjee A; Kannan S; Gupta T
    J Neurooncol; 2024 Mar; 167(1):189-198. PubMed ID: 38265748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm.
    Guo Y; Ma Z; Pei D; Duan W; Guo Y; Liu Z; Guan F; Wang Z; Xing A; Guo Z; Luo L; Wang W; Yu B; Zhou J; Ji Y; Yan D; Cheng J; Liu X; Yan J; Zhang Z
    J Magn Reson Imaging; 2023 Oct; 58(4):1234-1242. PubMed ID: 36727433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A fusion model integrating magnetic resonance imaging radiomics and deep learning features for predicting alpha-thalassemia X-linked intellectual disability mutation status in isocitrate dehydrogenase-mutant high-grade astrocytoma: a multicenter study.
    Liu Z; Xu X; Zhang W; Zhang L; Wen M; Gao J; Yang J; Kan Y; Yang X; Wen Z; Chen S; Cao X
    Quant Imaging Med Surg; 2024 Jan; 14(1):251-263. PubMed ID: 38223098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Multicenter Study on Preoperative Assessment of Lymphovascular Space Invasion in Early-Stage Cervical Cancer Based on Multimodal MR Radiomics.
    Wu Y; Wang S; Chen Y; Liao Y; Yin X; Li T; Wang R; Luo X; Xu W; Zhou J; Wang S; Bu J; Zhang X
    J Magn Reson Imaging; 2023 Nov; 58(5):1638-1648. PubMed ID: 36929220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
    Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
    J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MR textural analysis on T
    Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z
    J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of High-Risk Cytogenetic Status in Multiple Myeloma Based on Magnetic Resonance Imaging: Utility of Radiomics and Comparison of Machine Learning Methods.
    Liu J; Zeng P; Guo W; Wang C; Geng Y; Lang N; Yuan H
    J Magn Reson Imaging; 2021 Oct; 54(4):1303-1311. PubMed ID: 33979466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A.
    Leske H; Blakstad H; Lund-Iversen M; Skovholt EK; Niehusmann P; Ramm-Pettersen JT; Skogen K; Kongelf G; Sprauten M; Magelssen H; Brandal P
    Neuropathology; 2023 Oct; 43(5):385-390. PubMed ID: 36754566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymph node metastasis prediction and biological pathway associations underlying DCE-MRI deep learning radiomics in invasive breast cancer.
    Liu W; Chen W; Xia J; Lu Z; Fu Y; Li Y; Tan Z
    BMC Med Imaging; 2024 Apr; 24(1):91. PubMed ID: 38627678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
    Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
    Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter clinical radiomics-integrated model based on [
    Zhang L; Pan H; Liu Z; Gao J; Xu X; Wang L; Wang J; Tang Y; Cao X; Kan Y; Wen Z; Chen J; Huang D; Chen S; Li Y
    Eur Radiol; 2023 Feb; 33(2):872-883. PubMed ID: 35984514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.